Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3
Summary
DARPA is soliciting proposals for Task Area 3 of the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program, which aims to develop a deployable, regulatory‑approved system of shelf‑stable blood analog components for use in austere pre‑hospital settings. The effort builds on prior DARPA work under the Fieldable Solutions for Hemorrhage with bio‑Artificial Resuscitation Products (FSHARP) program and focuses on advancing manufacturing scalability, clinical validation, and fielding technologies to bridge laboratory breakthroughs to real‑world medical use.